Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Revenue:    
Contract research revenue $ 14,969 $ 0
Costs and Expenses:    
Research and development 2,384,218 921,711
General and administrative 2,117,975 1,315,777
Total costs and expenses 4,502,193 2,237,488
Loss from operations (4,487,224) (2,237,488)
Other income/(expense), net (8,893) (7,122)
Net loss (4,496,117) (2,244,610)
Inducement charge from exercise of warrants (16,741,356) 0
Net loss attributable to common shareholders $ (21,237,473) $ (2,244,610)
Net loss available for common shareholders per share - basic and diluted (in dollars per share) $ (0.25) $ (0.04)
Weighted average common shares outstanding:    
Basic and diluted (in shares) 84,595,597 57,287,955